Top News

Apr 21, 2017
The agency approved Renflexis, a biosimilar to Janssen’s blockbuster rheumatoid arthritis treatment.
Apr 13, 2017
UC Berkeley appealed the February 2017 decision that determined Harvard and MIT’s Broad Institute and Berkeley’s CRISPR-Cas9 technologies were separately patentable.
Mar 29, 2017
The mAb is the first approved treatment that targets the progressive form of the disease.
Mar 16, 2017
By BioPharm International Editors
Human antibody for Zika virus could help in the treatment and prevention of the infection.
Mar 13, 2017
Trump’s choice for FDA commissioner faces drug pricing, regulatory, and approval challenges.
Mar 10, 2017
The White House said President Trump will nominate Scott Gottlieb to the position of FDA commissioner.
Mar 02, 2017
The Mutual Recognition Agreement will allow FDA and EU inspectors to recognize each other’s work and avoid the duplication of drug inspections.
Feb 16, 2017
The Patent Trial and Appeal Board ruled in favor of the Broad Institute, allowing the institution to keep patents for its CRISPR-Cas9 gene-editing technology.
Feb 16, 2017
PhRMA submits comments to the The Office of the United States Trade Representative encouraging protection of US innovation in foreign markets.
Feb 14, 2017
Evaluate and BioPharm International highlight the antibody-based therapeutics that may have 2017 launch dates in the United States.
lorem ipsum